Discover key Q3 2025 earnings insights for REGENXBIO (RGNX): gene therapy milestones, FDA progress, financial outlook, and upcoming pivotal trial data.
Lehigh researchers create new method that improves consistency between predicted and observed data. An international team of mathematicians led by Lehigh University statistician Taeho Kim has ...
The authors used a Bayesian modeling framework to fit behavior and serotonin neuron activity to reward history across multiple timescales. A key goal was to distinguish value coding from other ...
In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and ...
Get the latest on Lineage Cell Therapeutics' Q3 2025 earnings: clinical advances in OpRegen, new partnerships, and extended cash runway.
Check out which players are running hot or cold headed into Week 11 and what it might mean for your start-sit decisions.
A new era is born.
ProKidney (PROK) presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with advanced CKD and diabetes. The ...
Mortgages have downshifted a bit from highs earlier in the week but continue to fluctuate with the latest economic news. Retail sales were up more than expected, and jobless claims were down, showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback